Accès gratuit
Med Sci (Paris)
Volume 25, Numéro 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1145 - 1148
Section III - Un futur en développement
Publié en ligne 15 décembre 2009
  1. Inglesby TV, O’Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002; 287 : 2236–52.
  2. Binder P, Lepick O. Les armes biologiques. Paris : PUF, 2001.
  3. Mayor S. UK doctors warned after ricin poison found in police raid. Br Med J 2003; 326 : 126.
  4. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates ? Nat Rev Drug Discov 2004; 3 : 711–5.
  5. Sawada-Hirai R, Jiang I, Wang F, et al. Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J Immune Based Ther Vaccines 2004; 2 : 5.
  6. Little SF, Leppla SH, Cora E. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect Immun 1988; 56 : 1807–13.
  7. Little SF, Ivins BE, Fellows PF, Friedlander AM. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun 1997; 65 : 5171–5.
  8. Wild MA, Xin H, Maruyama T, et al. Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat Biotechnol 2003; 21 : 1305–6.
  9. Mohamed N, Clagett M, Li J, et al. A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun 2005; 73 : 795–802.
  10. Wang F, Ruther P, Jiang I, et al. Human monoclonal antibodies that neutralize anthrax toxin by inhibiting heptamer assembly. Hum Antibodies 2004; 13 : 105–10.
  11. Laffly E, Danjou L, Condemine F, et al. Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob Agents Chemother 2005; 49 : 3414–20.
  12. Pelat T, Hust M, Laffly E, et al. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother 2007; 51 : 2758–64.
  13. Baillie LSL, Quinn C, Swann P, et al. Expert Consultation on Monoclonal Antibodies for Anthrax rPA. 2003. Online :
  14. Jones SM, Ellis JF, Russell P, et al. Passive protection against Burkholderia pseudomallei infection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins. J Med Microbiol 2002; 51 : 1055–62.
  15. Hill J, Eyles JE, Elvin SJ, et al. Administration of antibody to the lung protects mice against pneumonic plague. Infect Immun 2006; 74 : 3068–70.
  16. Chen Z, Earl P, Americo J, et al. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci USA 2006; 103 : 1882–7.
  17. Su HP, Golden JW, Gittis AG, et al. Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology 2007; 368 : 331–41.
  18. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001; 285 : 1059–70.
  19. Foxwell BM, Detre SI, Donovan TA, Thorpe PE. The use of anti-ricin antibodies to protect mice intoxicated with ricin. Toxicology 1985; 34 : 79–88.
  20. Dubel S. Handbook of therapeutic antibodies. Weinheim : Wiley-VCH, 2007.
  21. Amersdorfer P, Wong C, Smith T, et al. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries.Vaccine 2002; 20 : 1640–8.
  22. Chen Z, Earl P, Americo J, et al. Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol 2007; 81 : 8989–95.
  23. Choi TK, Hollenbach PW, Pearson BE, et al. Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome. Nat Genet 1993; 4 : 117–23.
  24. Fishwild DM, O’Donnell SL, Bengoechea T, et al. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 1996; 14 : 845–51.
  25. Bellet D, Pecking A, Dangles-Marie V. XenoMouse : un tour de force pour l’obtention d’anticorps humains chez la souris. Med Sci (Paris) 2008 24 : 903–5.
  26. Barbas CF. Phage display: a laboratory manual. New York : Cold Spring Harbor Laboratory Press, 2001.
  27. Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 2008 36 : W503–8.
  28. Whitelegg NR, Rees AR. WAM: an improved algorithm for modelling antibodies on the WEB. Protein Eng 2000; 13 : 819–24.
  29. Pelat T, Bedouelle H, Rees AR, et al. Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol 2008; 384 : 1400–7.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.